The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Updated safety & durability results for CAR-T lisocabtagene maraleucel in NHL
Jeremy Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses updated results from the TRANSCEND-NHL-001 trial (NCT02631044) of the CAR T-cell product lisocabtagene maraleucel for the treatment of relapsed/refractory B-cell Non-Hodgkin lymphoma. Prof. Abramsom highlights the very promising results, including respose rates and durability. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
